Evermay Wealth Management LLC Sells 374 Shares of Boston Scientific Co. (NYSE:BSX)

Evermay Wealth Management LLC decreased its position in shares of Boston Scientific Co. (NYSE:BSX) by 47.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 419 shares of the medical equipment provider’s stock after selling 374 shares during the period. Evermay Wealth Management LLC’s holdings in Boston Scientific were worth $29,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BSX. Mutual Advisors LLC raised its stake in Boston Scientific by 20.7% during the 4th quarter. Mutual Advisors LLC now owns 5,999 shares of the medical equipment provider’s stock worth $347,000 after acquiring an additional 1,029 shares during the period. HB Wealth Management LLC grew its holdings in Boston Scientific by 2.2% during the 4th quarter. HB Wealth Management LLC now owns 19,071 shares of the medical equipment provider’s stock valued at $1,102,000 after buying an additional 404 shares in the last quarter. Raymond James & Associates grew its holdings in Boston Scientific by 3.9% during the 4th quarter. Raymond James & Associates now owns 1,181,574 shares of the medical equipment provider’s stock valued at $68,307,000 after buying an additional 44,000 shares in the last quarter. CVA Family Office LLC purchased a new stake in Boston Scientific during the 4th quarter valued at approximately $102,000. Finally, Raymond James Financial Services Advisors Inc. grew its holdings in Boston Scientific by 3.0% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 507,550 shares of the medical equipment provider’s stock valued at $29,341,000 after buying an additional 14,723 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Insiders Place Their Bets

In other Boston Scientific news, EVP John Bradley Sorenson sold 17,587 shares of the business’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $71.50, for a total value of $1,257,470.50. Following the completion of the transaction, the executive vice president now directly owns 50,638 shares in the company, valued at $3,620,617. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $77.30, for a total transaction of $539,785.90. Following the transaction, the executive vice president now owns 42,908 shares in the company, valued at $3,316,788.40. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP John Bradley Sorenson sold 17,587 shares of the company’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $71.50, for a total transaction of $1,257,470.50. Following the transaction, the executive vice president now owns 50,638 shares in the company, valued at approximately $3,620,617. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 72,259 shares of company stock worth $5,344,014. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Trading Down 4.5 %

Shares of NYSE:BSX traded down $3.50 on Thursday, hitting $74.26. 10,900,652 shares of the company’s stock were exchanged, compared to its average volume of 6,285,901. Boston Scientific Co. has a 12 month low of $48.35 and a 12 month high of $79.43. The stock has a market capitalization of $108.95 billion, a price-to-earnings ratio of 62.40, a price-to-earnings-growth ratio of 2.70 and a beta of 0.78. The business’s 50 day simple moving average is $76.48 and its two-hundred day simple moving average is $70.20. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.66 and a quick ratio of 1.14.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.04. The business had revenue of $4.12 billion during the quarter, compared to the consensus estimate of $4.02 billion. Boston Scientific had a return on equity of 16.39% and a net margin of 12.06%. The business’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same period last year, the company earned $0.53 earnings per share. Analysts anticipate that Boston Scientific Co. will post 2.32 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. JPMorgan Chase & Co. increased their price objective on shares of Boston Scientific from $82.00 to $85.00 and gave the company an “overweight” rating in a report on Thursday. UBS Group increased their price objective on shares of Boston Scientific from $74.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, April 25th. Robert W. Baird increased their price objective on shares of Boston Scientific from $90.00 to $91.00 and gave the company an “outperform” rating in a report on Thursday. Truist Financial raised their target price on shares of Boston Scientific from $86.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, July 16th. Finally, Citigroup raised their target price on shares of Boston Scientific from $87.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, July 10th. Two equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $84.76.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.